Program
irinotecan sucrosofate
Also written as “Irinotecan liposome injection”, “PEP02” and “Irinotecan Liposome Injection”.
Its studies are mostly in Pancreatic Neoplasms · Small Cell Lung Carcinoma · Breast Neoplasms · Esophageal Squamous Cell Carcinoma · Cholangiocarcinoma, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 50 open or running | phase 2since Jan 18, 2021 | Jul 20, 2020 | none ahead |
| PharmaEngine | 50 open or running | phase 2since Dec 18, 2008 | Dec 18, 2008 | none ahead |
| Ipsen | 40 open or running | phase 3since Mar 9, 2017 | Dec 19, 2012 | none ahead |
| Cardiff Oncology | 10 open or running | phase 2since Feb 9, 2021 | Feb 9, 2021 | none ahead |
| Jiangsu HengRui Medicine | 10 open or running | phase 1since Sep 29, 2021 | Sep 29, 2021 | none ahead |
| Merrimack Pharmaceuticals | 10 open or running | phase 3since Dec 14, 2011 | Dec 14, 2011 | none ahead |
| Shanghai Runshi Pharmaceutical Technology | 11 open or running | phase 2since Jul 9, 2024 | Jul 9, 2024 | none ahead |
| SONIRE Therapeutics | 11 open or running | early phase 1since Jun 5, 2025 | Jun 5, 2025 | Dec 1, 2026early phase 1 · NCT07033689 |
| Sorrento Therapeutics | 10 open or running | phase 3since Jul 26, 2019 | Jul 26, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Dec 18, 2008.
- Sep 10, 2015Phase 2 study in Pancreatic NeoplasmsIpsen · NCT02551991 · 56 enrolled · United States, Australia, Spain
- Aug 12, 2016Phase 1 study in Solid TumorPharmaEngine · NCT02884128 · 16 enrolled
- Mar 9, 2017Phase 3 study in Small Cell Lung CarcinomaIpsen · NCT03088813 · 491 enrolled · United States, Australia, Belgium and more
- Dec 21, 2018Phase 1 study in Refractory Solid TumorsPharmaEngine · NCT03810742 · 44 enrolled · Taiwan
- Jul 26, 2019Sorrento Therapeutics's first study: phase 3 study in Malignant Tumor of Pancreas Metastatic to LiverNew to Sorrento TherapeuticsSorrento Therapeutics · NCT04037241
- Jul 20, 2020CSPC Pharmaceutical Group's first study: phase 1 study in Advanced Pancreatic CancerNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT04482257 · 48 enrolled · China
- Jan 18, 2021Phase 1 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT04728035 · 119 enrolled · China
- Jan 18, 2021Phase 2 study in Small Cell Lung CarcinomaCSPC Pharmaceutical Group · NCT04727853 · 66 enrolled · China
- Feb 9, 2021Cardiff Oncology's first study: phase 2 study in Pancreatic Ductal AdenocarcinomaNew to Cardiff OncologyCardiff Oncology · NCT04752696 · 41 enrolled · United States
- Aug 4, 20212 phase 2 studiesCSPC Pharmaceutical Group · NCT05009953, NCT05047991
- Sep 29, 2021Jiangsu HengRui Medicine's first study: phase 1 study in Advanced Solid TumorsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT05086822 · 32 enrolled · China
- May 3, 2022Phase 1 study in Metastatic Pancreatic AdenocarcinomaIpsen · NCT05383352 · 177 enrolled · Australia, France, Germany and more
- Jul 9, 2024Shanghai Runshi Pharmaceutical Technology's first study: phase 2 study in Advanced Esophageal Squamous Cell CarcinomaNew to Shanghai Runshi Pharmaceutical TechnologyShanghai Runshi Pharmaceutical Technology · NCT06512428 · 138 planned · China
- Jun 5, 2025SONIRE Therapeutics's first study: early phase 1 study in Pancreatic NeoplasmsNew to SONIRE TherapeuticsSONIRE Therapeutics · NCT07033689 · 10 planned · United States
Ahead
- Dec 1, 2026Primary completion: early phase 1 study in Pancreatic NeoplasmsSONIRE Therapeutics · NCT07033689
TargetBeta
“DNA topoisomerase I inhibitor”ChEMBL 37, by rule
Other programs on TOP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Topotecanrule | GlaxoSmithKline | phase 3 | 33 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07033689Pancreatic Neoplasms · United States | Early 1 | Recruiting | SONIRE Therapeutics | Dec 1, 2026 | 10 |
| NCT06512428Advanced Esophageal Squamous Cell Carcinoma · China | 2 | Recruiting | Shanghai Runshi Pharmaceutical Technology | Jan 30, 2026 | 138 |
| NCT05383352Metastatic Pancreatic Adenocarcinoma · Australia, France, Germany and more | 1 | Completed | Ipsen | May 27, 2024 | 177 |
| NCT05086822Advanced Solid Tumors · China | 1 | Completed | Jiangsu HengRui Medicine | Aug 28, 2017 | 32 |
| NCT05047991Pancreatic Cancer Non-resectable | 2 | UNKNOWN | CSPC Pharmaceutical Group | Nov 2023 | 153 |
| NCT05009953Cholangiocarcinoma · China | 2 | Terminated | CSPC Pharmaceutical Group | Jan 16, 2023 | 17 |
| NCT04752696Pancreatic Ductal Adenocarcinoma · United States | 2 | Terminated | Cardiff Oncology | Dec 24, 2024 | 41 |
| NCT04728035Advanced Breast Cancer · China | 1 | Completed | CSPC Pharmaceutical Group | Jun 5, 2023 | 119 |
| NCT04727853Small Cell Lung Carcinoma · China | 2 | Completed | CSPC Pharmaceutical Group | Apr 26, 2022 | 66 |
| NCT04482257Advanced Pancreatic Cancer · China | 1 | UNKNOWN | CSPC Pharmaceutical Group | Dec 2020 | 48 |
| NCT04037241Malignant Tumor of Pancreas Metastatic to Liver | 3 | Withdrawn | Sorrento Therapeutics | Jan 1, 2022 | 0 |
| NCT03810742Refractory Solid Tumors · Taiwan | 1 | Completed | PharmaEngine | May 4, 2022 | 44 |
| NCT03088813Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 3 | Completed | Ipsen | Feb 8, 2022 | 491 |
| NCT02884128Solid Tumor | 1 | Completed | PharmaEngine | Aug 2008 | 16 |
| NCT02551991Pancreatic Neoplasms · United States, Australia, Spain | 2 | Completed | Ipsen | Feb 15, 2021 | 56 |
| NCT01770353Triple Negative Breast Neoplasms · United States | 1 | Completed | Ipsen | Oct 2, 2018 | 45 |
| NCT01494506Pancreatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merrimack Pharmaceuticals | Feb 2014 | 417 |
| NCT00940758Colorectal Neoplasms · Taiwan | 1 | Completed | PharmaEngine | May 2012 | 18 |
| NCT00813163Pancreatic Neoplasms · United States, Taiwan | 2 | Completed | PharmaEngine | Dec 2010 | 41 |
| NCT00813072Stomach Neoplasms · Bosnia and Herzegovina, Croatia, Korea, Republic of and more | 2 | Completed | PharmaEngine | Jul 2010 | 135 |
How it is read
Names in the registry
- “Irinotecan liposome injection”, 5 entries
- “PEP02”, 4 entries
- “Irinotecan Liposome Injection”, 3 entries
- “MM-398”, 2 entries
- “Nanoliposomal irinotecan”, 1 entry
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 6 studies
- Small Cell Lung Carcinoma, 2 studies
- Breast Neoplasms, 1 study
- Esophageal Squamous Cell Carcinoma, 1 study
- Cholangiocarcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.